InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,718.57
(
0.28%
)
US TECH 100
19,304.80
(
0.04%
)
Dow Jones
42,124.65
(
0.15%
)
Brent Oil
73.54
(
-0.47%
)
Bitcoin
63,378.08
(
-0.38%
)
Post# of 409
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

denzelwashington

Send PM Follow Ignore
Followers 0
Posts 4
Boards Moderated 0
Alias Born 01/10/2020

denzelwashington

Re: None

Friday, 01/10/2020 6:24:28 AM

Friday, January 10, 2020 6:24:28 AM

Post# of 409
Acthar seems to have competition on the horizon. The Swedish company SynAct Pharma has found what melanocortin receptors that work and which that really doesn't do anything.

The mechanism of action is not know in Acthar, 50+ years after its inception. All we know is that it targets MC1R-MC5R.

SynAct Pharma has recognized that MC1R and MC3R are the two MCs that are pulling the real weight in terms of efficacy. They will shortly announce interim analysis in their phase II-study. I believe that this will be the death blow to Acthar, but perhaps they are in talks of maybe acquiring SynAct in some form?

Anyone with more info?

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up